IJRAR.ORG E-ISSN: 2348-1269, P-ISSN: 2349-5138

INTERNATIONAL JOURNAL OF RESEARCH AND ANALYTICAL REVIEWS (IJRAR) | IJRAR.ORG

An International Open Access, Peer-reviewed, Refereed Journal

Fatty Liver Disease: A Silent Epidemic and Emerging Public Health Challenge in India

(Prof).Dr. Arun Kumar VN, Principal, JIET college of Nursing, Jodhpur, Rajasthan.

Mr.Hansraj Choubisa, Vice principal, Gokul Nursing College, Siddhpur, Gujarat.

Mr.Bharat Singh Banshiwal, Associate Professor, Geetanjali College of Nursing, Jaipur, Rajasthan.

Introduction

The liver is the largest internal organ and one of the most metabolically active organs in the human body. It performs more than 500 essential physiological functions, including carbohydrate metabolism, protein synthesis, lipid metabolism, detoxification, bile production, vitamin storage, and immune regulation. The liver possesses a remarkable ability to regenerate following injury; however, persistent metabolic stress and chronic inflammation eventually impair its regenerative capacity, resulting in irreversible fibrosis and cirrhosis.

Fatty liver disease is characterized by excessive accumulation of triglycerides within hepatocytes. Under normal physiological conditions, fat constitutes less than 5% of liver weight. When fat accumulation exceeds this threshold, hepatic steatosis develops. Persistent fat accumulation initiates oxidative stress, mitochondrial dysfunction, inflammatory responses, and fibrosis that may progress to liver failure and hepatocellular carcinoma.

Historically, fatty liver disease was categorized into alcoholic fatty liver disease (AFLD) and non-alcoholic fatty liver disease (NAFLD). In 2023, an international consensus replaced the term NAFLD with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) to better reflect the metabolic basis of the disease and eliminate the negative definition of "non-alcoholic." Patients with hepatic steatosis accompanied by obesity, type 2 diabetes mellitus, insulin resistance, hypertension, dyslipidaemia, or other metabolic abnormalities are now classified as having MASLD.

MASLD has become one of the most important public health challenges of the 21st century. Current evidence indicates that approximately one in every three adults worldwide has fatty liver disease. The prevalence continues to increase among children, adolescents, and young adults because of rising obesity, physical inactivity, excessive consumption of processed foods, and sugar-sweetened beverages.

India is experiencing a rapid epidemiological transition characterized by urbanization, sedentary occupations, changing dietary patterns, and increasing prevalence of obesity and diabetes mellitus. These changes have substantially increased the incidence of fatty liver disease. Urban populations demonstrate a higher prevalence compared with rural populations, although the disease is now increasingly recognized in rural communities as well.

The disease is often referred to as a "silent epidemic" because most individuals remain asymptomatic during the early stages. Consequently, many patients are diagnosed only after significant liver damage has occurred. Early identification through screening of high-risk individuals and timely lifestyle intervention can effectively reverse hepatic steatosis and prevent progression to advanced liver disease.

Nurses and other healthcare professionals play an indispensable role in health promotion, patient education, dietary counselling, weight management, diabetes control, and long-term follow-up. Community-based awareness programmes, early screening initiatives, and evidence-based lifestyle interventions are essential to reduce the growing burden of fatty liver disease in India.

Epidemiology of Fatty Liver Disease

Global Burden

Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most common chronic liver disease worldwide. Recent epidemiological studies estimate that approximately one-third of the global adult population is affected, making it a major contributor to chronic liver disease, cirrhosis, hepatocellular carcinoma, and liver-related mortality. The prevalence continues to rise in parallel with increasing obesity, type 2 diabetes mellitus, and metabolic syndrome.

MASLD has become one of the leading causes of liver transplantation in many developed countries. Beyond liver-related complications, individuals with MASLD have an increased risk of cardiovascular disease, chronic kidney disease, and several metabolic disorders, significantly increasing healthcare costs worldwide.

Epidemiology in India

India is experiencing a rapid rise in MASLD because of urbanization, sedentary lifestyles, unhealthy dietary habits, and increasing obesity. Community-based studies indicate that approximately 35–40% of Indian adults may have MASLD, although prevalence varies by region and population studied. A recent nationwide Phenome India cohort found an age-adjusted prevalence of approximately 39%, with higher rates among people with obesity, diabetes, and metabolic syndrome.

Hospital-based studies have reported even higher prevalence in patients attending diabetes and endocrinology clinics. Urban populations generally demonstrate a greater disease burden than rural populations because of lifestyle-related risk factors.

Regional Variations in India

The burden of MASLD differs considerably across India because of differences in genetics, diet, physical activity, and socioeconomic conditions. Recent multicentre studies have demonstrated a particularly high burden in North India, while substantial prevalence has also been observed in southern and western states.

Classification of Fatty Liver Disease

Modern nomenclature classifies steatotic liver disease into several categories:

1. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

MASLD is diagnosed when hepatic steatosis is present together with one or more cardio metabolic risk factors, including obesity, type 2 diabetes mellitus, hypertension, dyslipidaemia, or insulin resistance. It represents the most common form of fatty liver disease worldwide.

2. Metabolic Dysfunction-Associated Steatohepatitis (MASH)

MASH is the progressive inflammatory form of MASLD. It is characterized by hepatic steatosis with inflammation, hepatocyte injury, and varying degrees of fibrosis. Without treatment, MASH may progress to cirrhosis and hepatocellular carcinoma.

3. Alcohol-Related Liver Disease (ALD)

Alcohol-related liver disease results from chronic excessive alcohol consumption. Disease progression ranges from fatty liver to alcoholic hepatitis, fibrosis, cirrhosis, and liver failure.

4. Mixed Etiology Steatotic Liver Disease

Some individuals have both metabolic dysfunction and significant alcohol intake, resulting in overlapping disease mechanisms requiring individualized clinical management.

Etiology and Risk Factors

MASLD develops due to a combination of genetic, metabolic, environmental, and lifestyle factors that promote excessive fat accumulation in the liver.

Non-modifiable Risk Factors:

Increasing age, family history of liver disease, male sex (and post-menopausal women), genetic predisposition (e.g., PNPLA3 variants), and certain ethnic backgrounds.

Modifiable Risk Factors:

Central obesity, type 2 diabetes mellitus, dyslipidaemia, hypertension, metabolic syndrome, sedentary lifestyle, unhealthy high-calorie diet, sugar-sweetened beverages, excess refined carbohydrates, smoking, chronic alcohol consumption, sleep deprivation, and psychological stress.

The presence of multiple metabolic risk factors—particularly obesity, diabetes, hypertension, and dyslipidaemia—significantly increases the risk of progression from simple steatosis to MASH, advanced fibrosis, and cirrhosis.

Pathophysiology of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

The development of MASLD is a complex process involving metabolic dysfunction, insulin resistance, oxidative stress, inflammation, and fibrosis. The widely accepted "multiple-hit hypothesis" explains that several factors act simultaneously to promote liver injury rather than a single causative mechanism.

1. Insulin Resistance

Insulin resistance is the primary mechanism responsible for MASLD. Under normal conditions, insulin regulates glucose and lipid metabolism. However, when insulin resistance develops, adipose tissue releases excessive free fatty acids into the bloodstream. These fatty acids accumulate within hepatocytes, leading to hepatic steatosis.

2. Hepatic Fat Accumulation

The liver receives excess fatty acids from adipose tissue, dietary fat, and increased hepatic fat synthesis (de novo lipogenesis). When fat production exceeds fat oxidation and export, triglycerides accumulate within liver cells, causing steatosis.

3. Oxidative Stress

Excess fat within hepatocytes undergoes oxidation, producing reactive oxygen species (ROS). These highly reactive molecules damage cellular proteins, DNA, and mitochondria, leading to hepatocyte injury.

4. Inflammatory Response

Damaged hepatocytes release inflammatory mediators such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and transforming growth factor-beta (TGF-β). Persistent inflammation promotes progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH).

5. Fibrosis and Cirrhosis

Continuous inflammation activates hepatic stellate cells, which produce excessive collagen and extracellular matrix proteins. Progressive fibrosis eventually leads to cirrhosis, portal hypertension, liver failure, and hepatocellular carcinoma.

Clinical Manifestations

Early Stage:

MASLD is usually asymptomatic and is often detected incidentally during routine health check-ups or abdominal ultrasonography.

Common Symptoms:

When symptoms occur, patients may experience persistent fatigue, generalized weakness, mild right upper abdominal discomfort, abdominal fullness, reduced exercise tolerance, nausea, and unexplained weight changes.

Advanced Disease:

As the disease progresses to advanced fibrosis or cirrhosis, patients may develop hepatomegaly, splenomegaly, ascites, peripheral oedema, jaundice, spider angiomas, palmar erythema, muscle wasting, hepatic encephalopathy, and gastrointestinal bleeding due to portal hypertension.

Diagnostic Evaluation

Early diagnosis is important as MASLD is potentially reversible in its early stages.

Laboratory Investigations:

Liver function tests (ALT, AST, ALP, GGT), serum bilirubin, albumin, prothrombin time/INR, complete blood count, fasting blood glucose, HbA1c, lipid profile, and viral hepatitis markers are routinely performed. Thyroid function tests may be indicated in selected patients.

Non-invasive Assessment and Imaging:

Fibrosis scores such as FIB-4, NAFLD Fibrosis Score, and APRI help identify patients at risk of advanced fibrosis. Ultrasonography is the first-line imaging modality, while FibroScan (Transient Elastography) assesses liver stiffness non-invasively. MRI-PDFF provides accurate quantification of liver fat, and liver biopsy remains the gold standard for confirming MASH and staging fibrosis in selected cases.

Complications

If left untreated, MASLD may progress to MASH, liver fibrosis, cirrhosis, portal hypertension, liver failure, hepatocellular carcinoma, and may ultimately require liver transplantation. It is also associated with important extrahepatic complications, including type 2 diabetes mellitus, cardiovascular disease, chronic kidney disease, hypertension, dyslipidaemia, obstructive sleep apnoea, and increased overall mortality.

Disease Progression

Stage	Characteristics
Stage 1	**Simple hepatic steatosis:** Fat accumulation in the liver without significant inflammation or fibrosis.
Stage 2	**Metabolic dysfunction-associated steatohepatitis (MASH):** Hepatic steatosis with inflammation and hepatocellular injury, with or without early fibrosis.
Stage 3	**Liver fibrosis:** Progressive scarring of liver tissue due to chronic inflammation, increasing the risk of liver dysfunction.
Stage 4	**Cirrhosis:** Advanced fibrosis with permanent liver damage, impaired liver function, and complications such as portal hypertension.
Stage 5	**Hepatocellular carcinoma and liver failure:** End-stage liver disease with a high risk of liver cancer, liver failure, and the potential need for liver transplantation.

Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Principles of Management

The main goals of MASLD management are to reduce liver fat, prevent progression to MASH, fibrosis, and cirrhosis, improve insulin sensitivity, control metabolic disorders, reduce cardiovascular risk, and enhance quality of life. A multidisciplinary team involving physicians, nurses, dietitians, physiotherapists, and psychologists is essential for comprehensive care.

Lifestyle Modification

Lifestyle modification is the cornerstone of treatment. A 7–10% weight loss significantly improves liver inflammation, while ≥10% weight loss may reverse fibrosis in some patients. A Mediterranean-style diet rich in fruits, vegetables, whole grains, legumes, fish, and healthy fats is recommended, while sugary beverages, processed foods, fried foods, and alcohol should be avoided. Patients should perform 150–300 minutes of moderate-intensity aerobic exercise per week along with muscle-strengthening exercises at least twice weekly.

Medical and Surgical Management

Associated conditions such as obesity, type 2 diabetes, hypertension, and dyslipidaemia should be optimally controlled. Pharmacological therapy is mainly reserved for patients with MASH and significant fibrosis. Commonly used medications include Vitamin E**,** Pioglitazone**,** and GLP-1 receptor agonists (Semaglutide, Liraglutide, Tirzepatide). Newer therapies such as Resmetirom and other anti-fibrotic agents are emerging. Bariatric surgery may be considered for selected patients with severe obesity who do not respond to lifestyle interventions.

Nursing Management

Nurses play a key role by assessing nutritional status, BMI, waist circumference, physical activity, blood pressure, laboratory findings, and medication adherence. They provide education on healthy diet, regular exercise, weight reduction, alcohol and smoking cessation, medication compliance, stress management, and the importance of regular follow-up and monitoring.

Lifestyle Recommendations for Patients with MASLD

Component	Recommendation
Weight loss	**7–10%** of body weight
Diet	Mediterranean diet
Exercise	**≥150 minutes/week** of moderate-intensity activity
Alcohol	Complete avoidance or strict limitation
Smoking	Complete cessation

Component	Recommendation
Diabetes	Maintain good glycaemic control
Lipids	Regular monitoring and treatment
Follow-up	Every **3–6 months**

Prevention Strategies

Primary Prevention:

Primary prevention focuses on reducing the risk of MASLD through healthy lifestyle practices. It includes consuming a balanced diet rich in fruits, vegetables, whole grains, and lean proteins, limiting processed foods and sugary beverages, engaging in at least 150–300 minutes of moderate-intensity physical activity per week, maintaining a healthy body weight, and avoiding alcohol and tobacco use.

Secondary Prevention:

Secondary prevention aims at early detection and timely management. High-risk individuals, including those with obesity, type 2 diabetes, hypertension, dyslipidaemia, or metabolic syndrome, should undergo regular screening using liver function tests, abdominal ultrasonography, FIB-4 score, **and** FibroScan when indicated.

Tertiary Prevention:

Tertiary prevention focuses on slowing disease progression and improving quality of life through regular follow-up, monitoring of liver fibrosis, nutritional counselling, management of complications, lifestyle support, and referral for liver transplantation in advanced cases.

Public Health Implications

MASLD is an emerging public health challenge due to its increasing prevalence and close association with obesity, diabetes, and other non-communicable diseases. It contributes to increased healthcare costs, reduced productivity, higher cardiovascular morbidity and mortality, and a growing demand for advanced liver care. Integrating liver health into national NCD prevention programmes, promoting healthy lifestyles, strengthening community awareness, and implementing early screening strategies are essential to reduce the overall burden of MASLD.

Government Initiatives in India

The Government of India addresses risk factors for MASLD through the National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), Ayushman Bharat Health and Wellness Centres, population-based screening for adults aged 30 years and above, National Health Mission awareness campaigns, and AYUSH initiatives promoting yoga and healthy lifestyles. These programmes help reduce the

burden of fatty liver disease by encouraging early detection and prevention of obesity, diabetes, and metabolic disorders.

Future Directions

Future efforts should focus on developing non-invasive diagnostic biomarkers, AI-assisted diagnosis, precision medicine, novel drug therapies, gut microbiome research, community-based screening, long-term lifestyle intervention studies, and digital health technologies to improve early detection, monitoring, and management of MASLD.

Conclusion

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has emerged as one of the most important public health challenges of the twenty-first century. The disease affects millions of individuals worldwide and is increasingly prevalent in India due to rising obesity, diabetes, metabolic syndrome, and sedentary lifestyles.

Although MASLD is often asymptomatic during its early stages, timely diagnosis and lifestyle modification can reverse hepatic steatosis and prevent progression to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.

Healthcare professionals, particularly nurses, play a pivotal role in early identification, patient education, lifestyle counselling, and long-term monitoring. Strengthening community awareness, integrating liver health into non-communicable disease programmes, and promoting healthy lifestyle practices are essential to reduce the future burden of liver disease.

With continued research, emerging pharmacological therapies, and multidisciplinary management, the outlook for patients with MASLD is expected to improve substantially.

References (Vancouver Style)

1. Rinella ME, et al. Multisociety Delphi consensus statement on new fatty liver disease nomenclature. **Hepatology**. 2023.
2. European Association for the Study of the Liver (EASL). **Clinical Practice Guidelines on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)**. 2024.
3. American Association for the Study of Liver Diseases (AASLD). **Practice Guidance on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)**. 2024.
4. World Health Organization. **Noncommunicable Diseases Fact Sheet**. Geneva: WHO; 2025.
5. Indian Council of Medical Research. **Guidelines on Metabolic Disorders**. New Delhi: ICMR; 2024.
6. Younossi ZM, et al. Global epidemiology of metabolic dysfunction-associated steatotic liver disease. **Hepatology**. 2023.

7. Powell EE, et al. Natural history of metabolic dysfunction-associated steatotic liver disease. **Lancet Gastroenterol Hepatol**. 2024.
8. Chalasani N, et al. Management of metabolic dysfunction-associated steatotic liver disease. **Hepatology**. 2024.
9. Estes C, et al. Global burden of metabolic dysfunction-associated steatotic liver disease. **J Hepatol**. 2023.
10. Eslam M, et al. MASLD: A new era in fatty liver disease. **Nat Rev Gastroenterol Hepatol**. 2024.
11. Ministry of Health and Family Welfare, Government of India. **National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD)**. New Delhi: MoHFW; 2024.
12. National Centre for Disease Control. **Non-Communicable Disease Programme Report**. New Delhi: NCDC; 2024.
13. ICMR–National Institute of Nutrition. **Dietary Guidelines for Indians**. Hyderabad: ICMR-NIN; 2024.
14. American Diabetes Association. **Standards of Care in Diabetes—2025**. **Diabetes Care**. 2025.
15. World Obesity Federation. **Global Obesity Atlas 2025**. London: World Obesity Federation; 2025.
16. World Health Organization. **Global Action Plan for the Prevention and Control of Noncommunicable Diseases**. Geneva: WHO; 2025.
17. Sanyal AJ, et al. Emerging therapies for metabolic dysfunction-associated steatohepatitis. **N Engl J Med**. 2024.
18. Harrison SA, et al. Resmetirom for non-cirrhotic metabolic dysfunction-associated steatohepatitis. **N Engl J Med**. 2024.
19. Mantovani A, et al. Cardiovascular risk in metabolic dysfunction-associated steatotic liver disease. **J Hepatol**. 2024.
20. Lazarus JV, et al. Global policy recommendations for metabolic dysfunction-associated steatotic liver disease. **Lancet**. 2024.